菜单

Perspectives

From Challenge to Breakthrough: Driving Speed and Quality in BsAb Development
Jan. 20, 2026
From Challenge to Breakthrough: Driving Speed and Quality in BsAb Development

At the 2026 J.P. Morgan Healthcare Conference (JPM), WuXi Biologics announced that its bispecific/multispecific antibody business has become the company’s fastest-growing segment. This stellar performance serves as a powerful testament to the company’s industry-leading antibody development capabilities and innovative technologies.

 

WuXi Biologics has successfully slashed the industry-average cell line development timeline from 12 months to just 6 months, while consistently delivering exceptional titers, yields and product quality. These accomplishments are rooted in years of dedicated R&D expertise and relentless technological innovation. To date, the company has published nearly 200 papers on antibody R&D and manufacturing across nearly 60 professional journals, including International Journal of Pharmaceutics and Biotechnology and Bioengineering — with close to 40 publications specifically focusing on bispecific/multispecific antibodies, fully affirming its robust technical prowess and industry leadership in the field.

 

This article spotlights a featured contribution by Dr. Sherry Gu, Executive Vice President and Chief Technology Officer of WuXi Biologics, published in industry publication Contract Pharma. The piece delves into core challenges in bispecific antibody (BsAb) development, and outlines tailored solutions to boost product yield, stability and quality, thereby expediting the commercialization journey of BsAb products.

 

Click the link to read the full article:

From Challenge to Breakthrough: Driving Speed and Quality in BsAb Development | Contract Pharma